This page was reviewed under our medical and editorial policy by
Maurie Markman, MD, President, Medicine & Science
This page was updated on March 8, 2024.
Prostate cancer screening is a way of looking for the presence of cancer before any noticeable symptoms. Screening is intended to identify the cancer before it spreads to other areas of the body.
There are no universal screening recommendations for prostate cancer, but both the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) recommend that men talk to their health care providers about the benefits and risks of screening so they’re better equipped to make an informed decision.
The ACS recommends men should discuss the benefits and risks of prostate cancer screening with their doctors based on the following ages and risk factors:
The USPSTF, alternatively, recommends these prostate cancer screening guidelines:
Most any medical decision comes with benefits and potential risks, and prostate cancer screening is no exception. Prostate cancer may spread to other parts of the body, which may make it more difficult to treat. The benefits of prostate cancer screening include:
Some potential risk factors for prostate cancer screening and subsequent treatment include:
The doctor can explain how these benefits and harms may apply to the patient’s health and well-being.
Prostate cancer screening may include:
If a man decides to be screened for prostate cancer after talking with his doctor, the ACS recommends a PSA test and, in some cases, a digital rectal exam (DRE).
PSA screening is a blood test that measures PSA levels. In some men, PSA levels may be higher than normal when prostate cancer is present. However, PSA levels may also vary due to:
After a PSA test, the medical team will interpret the results. If further information is needed, a prostate biopsy may be performed. During a biopsy, a tissue sample is removed from the prostate and examined in a laboratory to look for the presence of cancer cells. A biopsy is the only way to definitively diagnose prostate cancer.
The digital rectal exam (DRE) is a lesser-used screening tool. During a DRE, a doctor will insert their finger, using lubrication and a glove, into the rectum to feel the prostate and check for signs of cancer. The USPSTF doesn’t recommend the DRE be used as a primary screening test as the evidence doesn’t suggest it’s beneficial.
It’s understandable that PSA screening may be a complicated decision for patients to make, since the need for the test, and its results, aren’t simple. Patients should discuss their questions and concerns about prostate cancer screening with their health care providers.